A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts

Oncotarget

Volumn 6, Issue 6, 2015, Pages 4126-4143

  De Luca, Anastasia ^a   Rotili, Dante ^b   Carpanese, Debora ^c   Lenoci, Alessia ^b   Calderan, Laura ^c   Scimeca, Manuel ^a   Mai, Antonello ^b   Bonanno, Elena ^a   Rosato, Antonio ^c,d   Geroni, Cristina ^e   Quintieri, Luigi ^c   Caccuri, Anna Maria ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e On kòs Pharma Consulting   (Italy)

Author keywords

6 ((7 nitrobenzo c 1,2,5 oxadiazoles; C Jun N terminal Kinase; Glutathione Transferase P1 1; Human Melanoma Xenografts

Indexed keywords

2 [2 [(7 NITROBENZO[C][1,2,5]OXADIAZOL 4 YL)THIO]ETHOXY]ETHAN 1 OL; 2 [2 [2 [(7 NITROBENZO[C][1,2,5]XADIAZOL 4 YL)THIO]ETHOXY]ETHOXY]ETHANOL; 6 [(7 NITROBENZO[C][1,2,5]OXADIAZOL 4 YL)THIO]HEXAN 1 OL; ANTINEOPLASTIC AGENT; CASPASE 3; GLUTATHIONE TRANSFERASE M2; GLUTATHIONE TRANSFERASE P1; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GSTP1 PROTEIN, HUMAN; OXADIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROPHILICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MELANOMA; MICE; OXADIAZOLES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924251939     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2798     Document Type: Article

References (35)

1. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005; 23:9001-7.
2. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, et al. Melanoma. J Natl Compr Canc Netw. 2009; 7:250-75.
3. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16:5-24.
4. Mannervik B, Castro VM, Danielson UH, Tahir MK, Hansson J, Ringborg U. Expression of class Pi glutathione transferase in human malignant melanoma cells. Carcinogenesis. 1987; 8:1929-32.
5. Townsend DM, Tew KD. The role of glutathione S-transferase in anti-cancer drug resistance. Oncogene. 2003; 22:7369-75.
6. Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem. 2009; 9:763-77.
7. Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri AM. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys. 2010; 500:116-22.
8. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res. 1999; 9:51-8.
9. Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, et al. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol. 1995; 147:1545-52.
10. Depeille P, Cuq P, Passagne I, Evrard A, Vian L. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer. 2005; 93:216-23.
11. Picco V, Pages G. Linking JNK Activity to the DNA Damage Response. Genes Cancer. 2013; 4:360-8.
12. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, et al. Regulation of JNK signaling by GSTp. EMBO J. 1999; 18:1321-34.
13. Wu Y, Fan Y, Xue B, Luo L, Shen J, Zhang S, et al. Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene. 2006; 25:5787-800.
14. De Luca A, Federici L, De Canio M, Stella L, Caccuri AM. New insights into the mechanism of JNK1 inhibition by glutathione transferase P1-1. Biochemistry. 2012; 51:7304-12.
15. De Luca A, Mei G, Rosato N, Nicolai E, Federici L, Palumbo C, et al. The fine-tuning of TRAF2-GSTP1-1 interaction: effect of ligand binding and in situ detection of the complex. Cell Death Dis. 2014; 5:e1015.
16. Ricci G, De Maria F, Antonini G, Turella P, Bullo A, Stella L, et al. 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem. 2005; 280:26397-405.
17. Turella P, Cerella C, Filomeni G, Bullo A, De Maria F, Ghibelli L, et al. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res. 2005; 65:3751-61.
18. Turella P, Filomeni G, Dupuis ML, Ciriolo MR, Molinari A, De Maria F, et al. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells. J Biol Chem. 2006; 281:23725-32.
19. Sau A, Filomeni G, Pezzola S, D'Aguanno S, Tregno FP, Urbani A, et al. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and-resistant human osteosarcoma cell lines. Mol Biosyst. 2012; 8:994-1006.
20. De Luca A, Pellizzari Tregno F, Sau A, Pastore A, Palumbo C, Alama A, et al. Glutathione S-transferase P1-1 as a target for mesothelioma treatment. Cancer Sci. 2013; 104:223-30.
21. Pellizzari Tregno F, Sau A, Pezzola S, Geroni C, Lapenta C, Spada M, et al. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX) on human melanoma. Eur J Cancer. 2009; 45:2606-17.
22. Tentori L, Dorio AS, Mazzon E, Muzi A, Sau A, Cuzzocrea S, et al. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer. 2011; 47:1219-30.
23. Awasthi YC, Sharma R, Singhal SS. Human glutathione S-transferases. Int J Biochem. 1994; 26:295-308.
24. Federici L, Lo Sterzo C, Pezzola S, Di Matteo A, Scaloni F, Federici G, et al. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione S-transferases. Cancer Res. 2009; 69:8025-34.
25. Rotili D, De Luca A, Tarantino D, Pezzola S, Forgione M, Morozzo Della Rocca B, et al. Synthesis and Structure-Activity Relationship of New Cytotoxic Agents Targeting Human Glutathione S-Transferases. Eur J Med Chem. 2015; 89:156-171.
26. Keppler D. Export pumps for glutathione S-conjugates. Free Radic Biol Med. 1999; 27:985-91.
27. Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med. 1987; 165:812-29.
28. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008; 14:342-6.
29. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 2003; 22:2034-44.
30. Lo Bello M, Battistoni A, Mazzetti AP, Board PG, Muramatsu M, Federici G, et al. Site-directed mutagenesis of human glutathione transferase P1-1. Spectral, kinetic, and structural properties of Cys-47 and Lys-54 mutants. J Biol Chem. 1995; 270:1249-53.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193:265-75.
32. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974; 249:7130-9.
33. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82:1107-12.
34. Teicher BA, Andrews PA. Anticancer drug development guide: preclinical screening, clinical trials, and approval. 2nd ed. Totowa, N.J.: Humana Press. 2004; Part II:99-124.
35. Carson FL, Hladik C. Histotechnology: a self-instructional text. 2nd ed. Chicago: ASCP Press. 1997; Chapter 6:114-123.